An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis - PubMed (original) (raw)

An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis

T W Huizinga et al. Ann Rheum Dis. 1996 Nov.

Abstract

Objective: Dysregulation of tumour necrosis factor alpha (TNF alpha) production is thought to be important in rheumatoid arthritis. Since pentoxifylline and thalidomide inhibit endotoxin induced TNF production in vitro, these drugs were tested in an open study in rheumatoid arthritis patients to assess toxicity, the effect on TNF production, and the antiarthritic effects.

Methods: 12 patients with active rheumatoid arthritis were treated with 1200 mg pentoxifylline and 100 mg thalidomide a day during 12 weeks. In addition, TNF production was assessed by ex vivo whole blood cultures stimulated with endotoxin.

Results: Adverse events such as xerostomia, drowsiness, and constipation occurred in almost all patients, which led to discontinuation in three. The drugs halved the TNF production capacity during treatment (ANOVA, P < 0.03) whereas production capacity of interleukin (IL) 6, IL-10, and IL-12 was not affected. Of the nine patients who completed the study, five fulfilled the ACR-20% response criteria after 12 weeks of treatment.

Conclusions: Although pentoxifylline/thalidomide reduced the production capacity of TNF, the benefit/side effects ratio was poor due to multiple adverse effects, while clinical observation suggests limited efficacy.

PubMed Disclaimer

Similar articles

• A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis.
  Austin AS, Mahida YR, Clarke D, Ryder SD, Freeman JG. Austin AS, et al. Aliment Pharmacol Ther. 2004 Jan 1;19(1):79-88. doi: 10.1046/j.1365-2036.2003.01809.x. Aliment Pharmacol Ther. 2004. PMID: 14687169 Clinical Trial.
• An open study of the anti-TNF alpha agent pentoxifylline in the treatment of rheumatoid arthritis.
  Dubost JJ, Soubrier M, Ristori JM, Beaujon G, Oualid T, Bussière JL, Sauvezie B. Dubost JJ, et al. Rev Rhum Engl Ed. 1997 Dec;64(12):789-93. Rev Rhum Engl Ed. 1997. PMID: 9476267 Clinical Trial.
• Anticytokine approaches to the treatment of anorexia and cachexia.
  Haslett PA. Haslett PA. Semin Oncol. 1998 Apr;25(2 Suppl 6):53-7. Semin Oncol. 1998. PMID: 9625384 Review.
• Thalidomide in the treatment of refractory rheumatoid arthritis.
  Keesal N, Wasserman MJ, Bookman A, Lapp V, Weber DA, Keystone EC. Keesal N, et al. J Rheumatol. 1999 Nov;26(11):2344-7. J Rheumatol. 1999. PMID: 10555888 Clinical Trial.
• Thalidomide: focus on its employment in rheumatologic diseases.
  Ossandon A, Cassarà EA, Priori R, Valesini G. Ossandon A, et al. Clin Exp Rheumatol. 2002 Sep-Oct;20(5):709-18. Clin Exp Rheumatol. 2002. PMID: 12412207 Review.

Cited by

• Angiogenesis as a target in rheumatoid arthritis.
  Koch AE. Koch AE. Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii60-7. doi: 10.1136/ard.62.suppl_2.ii60. Ann Rheum Dis. 2003. PMID: 14532152 Free PMC article. Review. No abstract available.
• Small therapeutic molecules for the treatment of inflammatory bowel disease.
  van Deventer SJ. van Deventer SJ. Gut. 2002 May;50 Suppl 3(Suppl 3):III47-53. doi: 10.1136/gut.50.suppl_3.iii47. Gut. 2002. PMID: 11953333 Free PMC article. Review.
• Thalidomide in dermatology: revisited.
  Hassan I, Dorjay K, Anwar P. Hassan I, et al. Indian J Dermatol. 2015 Mar-Apr;60(2):213. doi: 10.4103/0019-5154.152580. Indian J Dermatol. 2015. PMID: 25814738 Free PMC article.
• Pentoxifylline decreases allodynia and hyperalgesia in a rat model of neuropathic pain.
  Vakili A, Shirvanian M, Safakhah H, Rashidy-Pour A. Vakili A, et al. Daru. 2011;19(4):306-11. Daru. 2011. PMID: 22615674 Free PMC article.
• Extraintestinal Complications of Inflammatory Bowel Disease.
  van Bodegraven AA, Dijkmans BA, Lips P, Stoof TJ, Peña AS, Meuwissen SG. van Bodegraven AA, et al. Curr Treat Options Gastroenterol. 2001 Jun;4(3):227-243. doi: 10.1007/s11938-001-0035-1. Curr Treat Options Gastroenterol. 2001. PMID: 11469980

References

1. 1. Lancet. 1994 Jul 2;344(8914):1-2 - PubMed
2. 1. N Engl J Med. 1995 May 18;332(20):1351-62 - PubMed
3. 1. J Infect Dis. 1995 May;171(5):1317-22 - PubMed
4. 1. Br J Rheumatol. 1995 Apr;34(4):334-42 - PubMed
5. 1. J Rheumatol. 1995 Apr;22(4):625-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • HighWire
  • Ovid Technologies, Inc.
  • PubMed Central

• Medical

  • MedlinePlus Health Information